SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-013017
Filing Date
2023-02-21
Accepted
2023-02-17 20:46:30
Documents
15
Period of Report
2023-02-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea173968-8k_inmedpharma.htm   iXBRL 8-K 36389
2 NEWS RELEASE, DATED FEBRUARY 17, 2023 ea173968ex99-1_inmedpharma.htm EX-99.1 97113
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5102
  Complete submission text file 0001213900-23-013017.txt   356366

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20230217.xsd EX-101.SCH 3233
5 XBRL DEFINITION FILE inm-20230217_def.xml EX-101.DEF 26195
6 XBRL LABEL FILE inm-20230217_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE inm-20230217_pre.xml EX-101.PRE 22364
9 EXTRACTED XBRL INSTANCE DOCUMENT ea173968-8k_inmedpharma_htm.xml XML 3760
Mailing Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4
Business Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 23644973
SIC: 2834 Pharmaceutical Preparations